| Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses JR Barrett, S Belij-Rammerstorfer, C Dold, KJ Ewer, PM Folegatti, ... Nature medicine 27 (2), 279-288, 2021 | 347 | 2021 |
| Viral evasion of the complement system and its importance for vaccines and therapeutics J Mellors, T Tipton, S Longet, M Carroll Frontiers in immunology 11, 1450, 2020 | 71 | 2020 |
| Longitudinal antibody and T cell responses in Ebola virus disease survivors and contacts: an observational cohort study R Thom, T Tipton, T Strecker, Y Hall, JA Bore, P Maes, FR Koundouno, ... The Lancet Infectious Diseases 21 (4), 507-516, 2021 | 35 | 2021 |
| Divergent trajectories of antiviral memory after SARS-CoV-2 infection A Tomic, DT Skelly, A Ogbe, D O’Connor, M Pace, E Adland, F Alexander, ... Nature Communications 13 (1), 1251, 2022 | 29 | 2022 |
| Ebolavirus: comparison of survivor immunology and animal models in the search for a correlate of protection S Longet, J Mellors, MW Carroll, T Tipton Frontiers in Immunology 11, 599568, 2021 | 21 | 2021 |
| Oropouche virus cases identified in Ecuador using an optimised qRT-PCR informed by metagenomic sequencing EL Wise, S Márquez, J Mellors, V Paz, B Atkinson, B Gutierrez, S Zapata, ... PLoS neglected tropical diseases 14 (1), e0007897, 2020 | 15 | 2020 |
| Detection of Crimean-Congo Haemorrhagic Fever cases in a severe undifferentiated febrile illness outbreak in the Federal Republic of Sudan: A retrospective epidemiological and … H Bower, M El Karsany, M Alzain, B Gannon, R Mohamed, I Mahmoud, ... PLoS neglected tropical diseases 13 (7), e0007571, 2019 | 15 | 2019 |
| Complement-mediated neutralisation identified in Ebola virus disease survivor plasma: implications for protection and pathogenesis J Mellors, T Tipton, SK Fehling, J Akoi Bore, FR Koundouno, Y Hall, ... Frontiers in Immunology 13, 857481, 2022 | 13 | 2022 |
| Filovirus neutralising antibodies: mechanisms of action and therapeutic application A Hargreaves, C Brady, J Mellors, T Tipton, MW Carroll, S Longet Pathogens 10 (9), 1201, 2021 | 13 | 2021 |
| Characterisation of the T-cell response to Ebola virus glycoprotein amongst survivors of the 2013–16 West Africa epidemic TRW Tipton, Y Hall, JA Bore, A White, LS Sibley, C Sarfas, Y Yuki, ... Nature Communications 12 (1), 1153, 2021 | 13 | 2021 |
| An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females NG Marchevsky, G Li, P Aley, SAC Clemens, JR Barrett, ... EBioMedicine 81, 2022 | 11 | 2022 |
| Direct enhancement of viral neutralising antibody potency by the complement system: a largely forgotten phenomenon J Mellors, M Carroll Cellular and Molecular Life Sciences 81 (1), 22, 2024 | 2 | 2024 |
| Understanding the role of the complement system in Ebola virus and SARS-CoV-2 pathogenesis J Mellors PQDT-Global, 2022 | 1 | 2022 |
| Complement-Mediated Enhancement of SARS-CoV-2 Antibody Neutralisation Potency in Vaccinated Individuals J Mellors, R Dhaliwal, S Longet, T Tipton, E Barnes, S Dunachie, ... | | 2024 |
| Serological analysis in humans in Malaysian Borneo suggests prior exposure to H5 avian influenza H Klim, T William, C Brady, T Chua, HB Monzó, G Rajahram, J Mellors, ... | | 2024 |
| Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses (vol 27, pg 279, 2021) JR Barrett, S Belij-Rammerstorfer, C Dold, KJ Ewer, PM Folegatti, ... NATURE MEDICINE 27 (6), 1113-1113, 2021 | | 2021 |
